0024-1332 NDC - PLAVIX (CLOPIDOGREL)

Drug Information

Product NDC: 0024-1332

Proprietary Name: Plavix

Non Proprietary Name: clopidogrel

Active Ingredient(s):
  • 300 mg/1 CLOPIDOGREL BISULFATE


Administration Route(s): ORAL

Dosage Form(s): TABLET, FILM COATED

Pharmacy Class(es):
  • Cytochrome P450 2C8 Inhibitors [MoA];
  • Decreased Platelet Aggregation [PE];
  • P2Y12 Platelet Inhibitor [EPC];
  • P2Y12 Receptor Antagonists [MoA]

Labeler Information

Labeler Name: sanofi-aventis U.S. LLC
Product Type: HUMAN PRESCRIPTION DRUG
FDA Application Number: NDA020839
Marketing Category: NDA
Start Marketing Date:5/9/2009

Package Information

No. Package Code Package Description Billing Unit
10024-1332-303 BLISTER PACK in 1 CARTON (0024-1332-30) > 10 TABLET, FILM COATED in 1 BLISTER PACK

NDC Record

Field Name Field Value Definition
PRODUCT NDC0024-1332The labeler code and product code segments of the National Drug Code number, separated by a hyphen. Asterisks are no longer used or included within the product code segment to indicate certain configurations of the NDC.
PRODUCT TYPE NAMEHUMAN PRESCRIPTION DRUGIndicates the type of product, such as Human Prescription Drug or Human Over the Counter Drug. This data element matches the “Document Type” field of the Structured Product Listing.
PROPRIETARY NAMEPlavixThe proprietary name also known as the trade name is the name of the product chosen by the medication labeler for marketing purposes.
NON PROPRIETARY NAMEclopidogrelThe non-proprietary name is sometimes called the generic name. The generic name usually includes the active ingredient(s) of the product.
DOSAGE FORM NAMETABLET, FILM COATEDThe translation of the dosage form Code submitted by the firm.
ROUTE NAMEORALThe translation of the route code submitted by the firm, indicating route of administration.
START MARKETING DATE5/9/2009This is the date that the labeler indicates was the start of its marketing of the drug product.
MARKETING CATEGORY NAMENDAProduct types are broken down into several potential Marketing Categories, such as NDA/ANDA/BLA, OTC Monograph, or Unapproved Drug. One and only one Marketing Category may be chosen for a product, not all marketing categories are available to all product types. Currently, only final marketed product categories are included. The complete list of codes and translations can be found at www.fda.gov/edrls under Structured Product Labeling Resources.
APPLICATION NUMBERNDA020839This corresponds to the NDA, ANDA, or BLA number reported by the labeler for products which have the corresponding Marketing Category designated. If the designated Marketing Category is OTC Monograph Final or OTC Monograph Not Final, then the Application number will be the CFR citation corresponding to the appropriate Monograph (e.g. “part 341”). For unapproved drugs, this field will be null.
LABELER NAMEsanofi-aventis U.S. LLCName of Company corresponding to the labeler code segment of the Product NDC.
SUBSTANCE NAMECLOPIDOGREL BISULFATEThe following is the list of active ingredients in this product. An active ingredient is the substance responsible for the medicinal effects of a product specified by the substance's molecular structure or if the molecular structure is not known, defined by an unambiguous definition that identifies the substance. Each active ingredient name is the preferred term of the UNII code submitted.
ACTIVE NUMERATOR STRENGTH300 
ACTIVE INGRED UNITmg/1 
PHARM CLASSESCytochrome P450 2C8 Inhibitors [MoA], Decreased Platelet Aggregation [PE], P2Y12 Platelet Inhibitor [EPC], P2Y12 Receptor Antagonists [MoA] 

Download Record

Download this NDC record in Text format: Export

Download this NDC record in Excel (CSV) format: Export

Download this NDC record in XML format: Export

This page was last updated on: 9/15/2022